Nanoparticles as Drug Delivery Systems of RNAi in Cancer Therapy

Li, Diedie; Gao, Chengzhi; Kuang, Meiyan; Xu, Minhao; Wang, Ben; Luo, Yi; Teng, Lirong; Xie, Jing

doi:10.3390/molecules26082380

Cited by 22 publications

(18 citation statements)

References 178 publications

(71 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Third, genetic modification may cause biosafety problems with virus-based systems, such as adeno-associated viral vectors or lentiviral vectors, resulting in uncertain virus‒host interactions such as severe immune reactions and cancer progression 119 – 121 . To obtain eligible TDE inhibition with genetic manipulation, efforts should be devoted to developing an efficient and safe delivery system as well as targeting TDE-specific effectors 122 – 124 . To this end, the mechanism of TDE biogenesis and secretion should be well recognized, providing more potential targets for future translation.…”

Section: Current Challenges and Future Perspectivesmentioning

confidence: 99%

Targeted inhibition of tumor-derived exosomes as a novel therapeutic option for cancer

Chen

Duan

et al. 2022

Exp Mol Med

View full text Add to dashboard Cite

Mounting evidence indicates that tumor-derived exosomes (TDEs) play critical roles in tumor development and progression by regulating components in the tumor microenvironment (TME) in an autocrine or paracrine manner. Moreover, due to their delivery of critical molecules that react to chemotherapy and immunotherapy, TDEs also contribute to tumor drug resistance and impede the effective response of antitumor immunotherapy, thereby leading to poor clinical outcomes. There is a pressing need for the inhibition or removal of TDEs to facilitate the treatment and prognosis of cancer patients. Here, in the present review, we systematically overviewed the current strategies for TDE inhibition and clearance, providing novel insights for future tumor interventions in translational medicine. Moreover, existing challenges and potential prospects for TDE-targeted cancer therapy are also discussed to bridge the gaps between progress and promising applications.

show abstract

Section: Current Challenges and Future Perspectivesmentioning

confidence: 99%

Targeted inhibition of tumor-derived exosomes as a novel therapeutic option for cancer

Chen

Duan

et al. 2022

Exp Mol Med

View full text Add to dashboard Cite

show abstract

“…Gene therapy using nucleic acids such as DNA and RNA is an attractive and promising strategy for cancer treatment. In particular, small RNAs such as siRNA or miRNA generally bind to mRNAs and increase or decrease their activity to regulate gene expression [116,117]. Nano-based delivery systems such as liposomes, cationic polymers, and inorganic nanoparticles have been developed to protect these nucleic acids from degradation by endonuclease and deliver them to tumors [118,119].…”

Section: Nucleic Acidsmentioning

confidence: 99%

Recent Advances in Exosome-Based Drug Delivery for Cancer Therapy

Kim

Jang

Cho

et al. 2021

Cancers

View full text Add to dashboard Cite

Exosomes are a class of extracellular vesicles, with a size of about 100 nm, secreted by most cells and carrying various bioactive molecules such as nucleic acids, proteins, and lipids, and reflect the biological status of parent cells. Exosomes have natural advantages such as high biocompatibility and low immunogenicity for efficient delivery of therapeutic agents such as chemotherapeutic drugs, nucleic acids, and proteins. In this review, we introduce the latest explorations of exosome-based drug delivery systems for cancer therapy, with particular focus on the targeted delivery of various types of cargoes.

show abstract

“…However, the nanodelivery of therapeutic RNAs still suffers some limitations which might hinder their clinical translation [ 177 ]. For instance, lipid-based NPs suffer from rapid release rates and short half-lives in the systemic circulation.…”

Section: Modern Rna-based Therapeutic Modalitiesmentioning

confidence: 99%

Molecular Engines, Therapeutic Targets, and Challenges in Pediatric Brain Tumors: A Special Emphasis on Hydrogen Sulfide and RNA-Based Nano-Delivery

Fahmy¹,

Dawoud

Zeinelabdeen

et al. 2022

Cancers

View full text Add to dashboard Cite

Pediatric brain tumors represent a formidable challenge in the field of oncology. Pediatric brain tumors are sub-classified into several molecular sub-types, where each one is characterized by an array of hyperactivated oncogenic molecular engines. However, there have been great efforts dedicated to portray the involved signaling pathways driving pediatric brain tumors. Yet, a full understanding of the intertwined oncogenic pathways involved is still obscure. In this review, the authors shed light on novel therapeutic targets tailored for several sub-types of pediatric brain tumors and point out the limitations of such therapeutic approaches. Hydrogen Sulfide (H2S) has recently been cast as an oncogenic driver in several solid malignancies, yet its role in brain tumors is still under investigation. The authors also highlight the possible involvement of H2S in pediatric brain tumors and propose promising brain-delivery strategies for the sake of achieving better therapeutic results for brain tumors patients.Abstract: Pediatric primary brain tumors represent a real challenge in the oncology arena. Besides the psychosocial burden, brain tumors are considered one of the most difficult-to-treat malignancies due to their sophisticated cellular and molecular pathophysiology. Notwithstanding the advances in research and the substantial efforts to develop a suitable therapy, a full understanding of the molecular pathways involved in primary brain tumors is still demanded. On the other hand, the physiological nature of the blood–brain barrier (BBB) limits the efficiency of many available treatments, including molecular therapeutic approaches. Hydrogen Sulfide (H2S), as a member of the gasotransmitters family, and its synthesizing machinery have represented promising molecular targets for plentiful cancer types. However, its role in primary brain tumors, generally, and pediatric types, particularly, is barely investigated. In this review, the authors shed the light on the novel role of hydrogen sulfide (H2S) as a prominent player in pediatric brain tumor pathophysiology and its potential as a therapeutic avenue for brain tumors. In addition, the review also focuses on the challenges and opportunities of several molecular targeting approaches and proposes promising brain-delivery strategies for the sake of achieving better therapeutic results for brain tumor patients.

show abstract

Nanoparticles as Drug Delivery Systems of RNAi in Cancer Therapy

Cited by 22 publications

References 178 publications

Targeted inhibition of tumor-derived exosomes as a novel therapeutic option for cancer

Targeted inhibition of tumor-derived exosomes as a novel therapeutic option for cancer

Recent Advances in Exosome-Based Drug Delivery for Cancer Therapy

Molecular Engines, Therapeutic Targets, and Challenges in Pediatric Brain Tumors: A Special Emphasis on Hydrogen Sulfide and RNA-Based Nano-Delivery

Contact Info

Product

Resources

About